Latest Advances in Lung Cancer Research

Drs. Riely and Levy explain the necessity of reflex genomic testing in lung cancer to ensure personalized treatment and better patient outcomes.

Clinical cancer informatics research applying computational methods or digital health technologies to improve cancer care and patient outcomes.

Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.

Dr. Suresh S. Ramalingam urges community oncologists to use molecular testing and expand lung-cancer screening — so more patients gain access to modern, personalized therapies.

Dr. Suresh Ramalingam, a top cancer expert at Emory University, urges community oncologists to prioritize biomarker testing and lung cancer screening to ensure every patient benefits from the latest treatment breakthroughs — because advances only matter if all patients can access them.

Research develops hypoxic gene expression signatures to predict which muscle-invasive bladder cancer patients will respond to hypoxia-modifying therapies.

A major Australian-Canadian lung cancer screening study found that 73% of high-risk participants had incidental findings during baseline CT scans, with 10% requiring clinical follow-up, highlighting significant inconsistencies in how these findings are reported to doctors and raising important questions about standardization as Australia prepares to launch its national screening program in 2025.

Researchers developed RARE-seq, an ultrasensitive blood test detecting cell-free RNA that identifies early-stage lung cancer and monitors treatment resistance.

Chest CT scans used for lung cancer screening can do more than just find early lung cancer. These scans can also detect heart problems and early emphysema, offering a three-in-one health check for people at risk.

Early detection of incidental lung nodules can lead to timely treatment and improved survival rates for lung cancer patients.

Final clinical trial results demonstrate selpercatinib’s safety and efficacy in treating RET fusion-positive non-small cell lung cancer patients.

Scientists develop a groundbreaking urine test that detects “zombie” cell proteins, enabling early detection of lung cancer and potentially improving patient outcomes and prognosis.